Heltra: Explore Life – Discover More – Live Better

BeiGene stock rises on FDA fast track tag for investigational cancer therapy (NASDAQ:BGNE)

FDA headquarters in Washington DC.

JHVEPhoto

  • BeiGene (NASDAQ:BGNE) has acquired FDA Fast Track Designation for its investigational cancer therapy.
  • BGB-16673, an orally accessible BTK-targeting chimeric degradation activation compound, gained fast track standing for the remedy of grownup sufferers with relapsed or refractory power lymphocytic leukemia or small lymphocytic

Source: Seekingalpha

ADVERTISEMENT